ORIC Pharmaceuticals, Inc. — Form 8-K Summary
Business context and reporting period
ORIC Pharmaceuticals, Inc. filed a Form 8-K on August 10, 2021, under Item 2.02 and Item 9.01. The filing announces the release of financial results for the fiscal quarter ended June 30, 2021. ORIC is a Delaware corporation listed on Nasdaq under the symbol ORIC.
Financial results and liquidity
The filing itself does not provide revenue, net loss, cash flow, operating expense, margin, debt, cash, or liquidity figures. It incorporates by reference a press release dated August 10, 2021 as Exhibit 99.1, but the supplied filing text does not include the press release contents.
Material changes versus the prior comparable period
The filing text does not provide sufficient financial data to assess changes from the prior comparable period.
Guidance, outlook, risks, and unusual items
No guidance, outlook, management commentary, risk updates, contingencies, or unusual items are described in the supplied text. The reported information was furnished under Item 2.02 and is expressly not deemed filed for purposes of Section 18 of the Exchange Act, except as otherwise specified.
Key facts for investors to verify
- Obtain and review Exhibit 99.1 for the quarter’s financial results and management commentary.
- Verify cash and cash equivalents, operating cash burn, net loss, research and development expense, and remaining liquidity runway.
- Review any disclosed clinical, regulatory, financing, or corporate developments accompanying the quarterly results.
- Confirm whether the company provided updated guidance or identified material risks and contingencies.